

Minneapolis Heart Institute Foundation Cardiovascular Grand Rounds

CloudCME ID: 1240

Text ID to: 844-939-3950 (your email must be paired)

DATE: February 02, 2026 TIME: 7:00 AM - 8:00 AM

LOCATION: MHI Building - MHIF Suite 100
Learning Center - Virtual Zoom

TOPIC(S) OR TITLE: Myocarditis: 2026 Update on Management

FACULTY:

Leslie T Cooper, MD

Elizabeth C. Lane, Ph.D. and M. Nadine Zimmerman, Ph.D. Professor of Internal Medicine

Mayo Clinic - Florida

OVERVIEW/PURPOSE STATEMENT:

Our Cardiovascular Grand Rounds offers physicians and other health care providers the opportunity to review and discuss the latest developments in cardiovascular care every Monday morning during our Grand Rounds seasons. These weekly meetings feature topics across the spectrum of cardiovascular medicine. Practitioners share research highlights, offer treatment or diagnostic best practices, and collaborate to improve care for those with cardiovascular disease.

OVERALL OBJECTIVES:

1. Demonstrate improved awareness of emerging cardiovascular clinical care standards derived from new research
2. Discuss the implications of new cardiovascular care guidelines and develop more standardized approaches to treating cardiovascular disease
3. Utilize current evidence based guidelines to improve standards of care for individuals with cardiovascular diseases

Location: MHI Building - MHIF Suite 100 Learning Center - Virtual Zoom

Specialties: Cardiovascular Disease

LECTURE-SPECIFIC OBJECTIVES:

1. Recognize the 4 stages of myocarditis described in the 2025 ACC Expert Care Decision Pathway and how management varies with disease stage and presentation.
2. Describe the clinical, imaging and histologic predictors of death, ventricular arrhythmia and heart transplantation in acute myocarditis.
3. Differentiate the treatment of lymphocytic myocarditis from giant cell myocarditis and immune checkpoint inhibitor myocarditis.

Regularly Scheduled Series

Continuing Medical Education (CME)



DISCLOSURE POLICY AND STATEMENTS:

Allina Health, Office of Accreditation intends to provide balance, independence, objectivity, and scientific rigor in all of its educational activities and will adhere to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. The ACCME defines an ineligible company as "any entity" whose primary business is producing, marketing, re-selling, or distributing health care products/services used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

Any individual in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests) that have existed **WITHIN THE LAST 24 MONTHS**, even if it has now ended. All relevant financial relationships/conflicts of interest have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Lin Anderson, Other	Activity Coordinator	Nothing to disclose - 12/29/2025
Leslie T Cooper Jr., MD, Professor of Internal Medicine	Faculty	Consulting Fee-Bristol-Myers Squibb Company (Relationship has ended) Consulting Fee-Cardiol Therapeutics Consulting Fee-Moderna Consulting Fee-Foresee Pharmaceuticals (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Stromal Therapeutics - 01/12/2026
Ross Garberich, MS, MBA	Planning Committee Member	Nothing to disclose - 11/18/2025
David Hurrell, MD	Lead Physician	Consulting Fee-Boston Scientific Corporation - 11/21/2025
Cindy Resman, Other	Planning Committee Member	Nothing to disclose - 11/20/2025
John Rickert, BA	Activity Coordinator	Nothing to disclose - 11/10/2025
Scott Sharkey, MD	Planning Committee Member	Consulting Fee-Medtronic (Any division) - 11/20/2025